Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease

Transplant Infectious Disease

Volumn 16, Issue 3, 2014, Pages 440-449

  Gotoh, M ^a   Yoshizawa, S ^a   Katagiri, S ^a   Suguro, T ^a   Asano, M ^a   Kitahara, T ^a   Akahane, D ^a   Okabe, S ^a   Tauchi, T ^a   Ito, Y ^a   Ohyashiki, K ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Acute graft versus host disease; Allogeneic hematopoietic stem cell transplantation; Human herpesvirus 6

Indexed keywords

ACICLOVIR; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; FLUDARABINE; FOSCARNET; GANCICLOVIR; MELPHALAN; METHOTREXATE; PREDNISOLONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TACROLIMUS; VIRUS DNA;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SAMPLING; CANCER RADIOTHERAPY; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTINUOUS INFUSION; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS; DIAGNOSTIC TEST ACCURACY STUDY; DRUG MEGADOSE; ENGRAFTMENT; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HEMATOLOGIC MALIGNANCY; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; HUMAN TISSUE; INTESTINE BIOPSY; LEUKOCYTE COUNT; LIVER VENOOCCLUSIVE DISEASE; LOW DRUG DOSE; LYMPHOCYTE COUNT; MALE; MICROANGIOPATHY; NEUTROPHIL COUNT; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REDUCED INTENSITY CONDITIONING; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SHORT COURSE THERAPY; VIRUS LOAD; VIRUS REACTIVATION; WHOLE BODY RADIATION; ALLOTRANSPLANTATION; EXANTHEMA SUBITUM; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS ACTIVATION; VIRUS LATENCY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 6, HUMAN; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK FACTORS; ROSEOLOVIRUS INFECTIONS; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION; VIRUS LATENCY; YOUNG ADULT;

EID: 84901931310     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12229     Document Type: Article

References (40)

1. Takenaka K, Gondo H, Tanimoto K, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group. Bone Marrow Transplant 1997; 19 (3): 241-248.
2. Mori T, Mori S, Kanda Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2004; 33 (4): 431-434.
3. Dulery R, Salleron J, Dewilde A, et al. Early human herpesvirus type 6 reactivation after allogeneic stem cell transplantation: a large-scale clinical study. Biol Blood Marrow Transplant 2012; 18 (7): 1080-1089.
4. Jeulin H, Agrinier N, Guery M, et al. Human herpesvirus 6 infection after allogeneic stem cell transplantation: incidence, outcome, and factors associated with HHV-6 reactivation. Transplantation 2013; 95 (10): 1292-1298.
5. Fraser GA, Walker II; Canadian Blood and Marrow Transplant Group. Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations. Biol Blood Marrow Transplant 2004; 10 (5): 287-297.
6. Ljungman P, de la Camara R, Cordonnier C, et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT. Bone Marrow Transplant 2008; 42 (4): 227-240.
7. Maeda Y, Teshima T, Yamada M, et al. Monitoring of human herpesviruses after allogeneic peripheral blood stem cell transplantation and bone marrow transplantation. Br J Haematol 1999; 105 (1): 295-302.
8. Härmä M, Höckerstedt K, Lyytikäinen O, Lautenschlager I. HHV-6 and HHV-7 antigenemia related to CMV infection after liver transplantation. J Med Virol 2006; 78 (6): 800-805.
9. Halme L, Arola J, Höckerstedt K, Lautenschlager I. Human herpesvirus 6 infection of the gastroduodenal mucosa. Clin Infect Dis 2008; 46 (3): 434-439.
10. de Pagter PJ, Schuurman R, Visscher H, et al. Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome. Biol Blood Marrow Transplant 2008; 14 (7): 831-839.
11. Carrigan DR, Drobyski WR, Russler SK, Tapper MA, Knox KK, Ash RC. Interstitial pneumonitis associated with human herpesvirus-6 infection after marrow transplantation. Lancet 1991; 338 (8760): 147-149.
12. Cone RW, Hackman RC, Huang ML, et al. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Engl J Med 1993; 329 (3): 156-161.
13. Yamane A, Mori T, Suzuki S, et al. Risk factors for developing human herpesvirus 6 (HHV-6) reactivation after allogeneic hematopoietic stem cell transplantation and its association with central nervous system disorders. Biol Blood Marrow Transplant 2007; 13 (1): 100-106.
14. Ljungman P, Wang FZ, Clark DA, et al. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. Br J Haematol 2000; 111 (3): 774-781.
15. Radonić A, Oswald O, Thulke S, et al. Infections with human herpesvirus 6 variant B delay platelet engraftment after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005; 131 (4): 480-482.
16. Wang LR, Dong LJ, Zhang MJ, Lu DP. The impact of human herpesvirus 6B reactivation on early complications following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12 (10): 1031-1037.
17. Carreras E, Díaz-Beyá M, Rosiñol L, Martínez C, Fernández-Avilés F, Rovira M. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant 2011; 17 (11): 1713-1720.
18. Kalayoglu-Besisik S, Yenerel MN, Caliskan Y, Ozturk S, Besisik F, Sargin D. Time-related changes in the incidence, severity, and clinical outcome of hepatic veno-occlusive disease in hematopoietic stem cell transplantation patients during the past 10 years. Transplant Proc 2005; 37 (5): 2285-2289.
19. Uderzo C, Bonanomi S, Busca A, et al. Risk factors and severe outcome in thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Transplantation 2006; 82 (5): 638-644.
20. Qu L, Kiss JE. Thrombotic microangiopathy in transplantation and malignancy. Semin Thromb Hemost 2005; 31 (6): 691-699.
21. Kanda J, Saji H, Fukuda T, et al. Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study. Blood 2012; 119 (10): 2409-2416.
22. Nakai K, Kanda Y, Fukuhara S, et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia 2005; 19 (3): 396-401.
23. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15 (6): 825-828.
24. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991; 28 (3): 250-259.
25. Kanda Y, Mineishi S, Saito T, et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28 (7): 689-692.
26. Gondo H, Minematsu T, Harada M, et al. Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation. Br J Haematol 1994; 86 (1): 130-137.
27. Mori T, Okamoto S, Watanabe R, et al. Dose-adjusted preemptive therapy for cytomegalovirus disease based on real-time polymerase chain reaction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29 (9): 777-782.
28. Tanaka N, Kimura H, Iida K, et al. Quantitative analysis of cytomegalovirus load using a real-time PCR assay. J Med Virol 2000; 60 (4): 455-462.
29. Kimura H, Morita M, Yabuta Y, et al. Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay. J Clin Microbiol 1999; 37 (1): 132-136.
30. Tanaka N, Kimura H, Hoshino Y, et al. Monitoring four herpesviruses in unrelated cord blood transplantation. Bone Marrow Transplant 2000; 26 (11): 1193-1197.
31. Hara S, Kimura H, Hoshino Y, et al. Detection of herpesvirus DNA in the serum of immunocompetent children. Microbiol Immunol 2002; 46 (3): 177-180.
32. Kanda Y, Izutsu K, Hirai H, et al. Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. Leukemia 2004; 18 (5): 1013-1019.
33. Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80 (7): 1838-1845.
34. MacMillan ML, DeFor TE, Weisdorf DJ. The best endpoint for acute GVHD treatment trials. Blood 2010; 115 (26): 5412-5417.
35. Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M. Clinical outcomes of human herpesvirus 6 reactivation after hematopoietic stem cell transplantation. Clin Infect Dis 2005; 40 (7): 932-940.
36. Ogata M, Kikuchi H, Satou T, et al. Human herpesvirus 6 DNA in plasma after allogeneic stem cell transplantation: incidence and clinical significance. J Infect Dis 2006; 193 (1): 68-79.
37. Sashihara J, Tanaka-Taya K, Tanaka S, et al. High incidence of human herpesvirus 6 infection with a high viral load in cord blood stem cell transplant recipients. Blood 2002; 100 (6): 2005-2011.
38. Takatsuka H, Wakae T, Mori A, et al. Endothelial damage caused by cytomegalovirus and human herpesvirus-6. Bone Marrow Transplant 2003; 31 (6): 475-479.
39. Savolainen H, Lautenschlager I, Piiparinen H, Saarinen-Pihkala U, Hovi L, Vettenranta K. Human herpesvirus-6 and -7 in pediatric stem cell transplantation. Pediatr Blood Cancer 2005; 45 (6): 820-825.
40. Betts BC, Young JA, Ustun C, Cao Q, Weisdorf DJ. Human herpesvirus 6 infection after hematopoietic cell transplantation: is routine surveillance necessary? Biol Blood Marrow Transplant 2011; 17 (10): 1562-1568.